The Tidewater Building has reopened. Construction work may be ongoing on floors impacted by the fire and sprinkler damage. Please consult with your supervisor/unit head before returning and have patience as all building functions are returned to service.

Dongzhe Hong

PhD Candidate

Education & Affiliations

MSPH, Health Policy and Management, Emory University
MSc, Clinical Pharmacy & Pharmacy Administration, Peking University Health Science Center
BSc, Pharmaceutical Sciences, Peking University Health Science Center


Dongzhe Hong is currently a PhD candidate in the Department of Health Policy and Management at Tulane School of Public Health and Tropical Medicine. He has trained as a pharmacist (BS in Pharmaceutical sciences 2013, MS in Pharmacy Administration and Clinical Pharmacy 2015) through College of Pharmacy, Peking University Health Science Center. He has also trained health policy researcher (MSPH in Health Policy and Management 2017) through Emory University. He is the student president of Tulane Chapter for International Society for Pharmacoeconomics (ISPOR). His current research interests include health technology assessment, health policy, and health care quality, access, and economics. His previous works have evaluated the impacts of Medicaid expansion in Louisiana, examined the cost effectiveness of newly anti-diabetic drugs, and explored patient preferences for treatment of rare diseases, electronic medical record risk modeling of cardiovascular outcomes among patients with type 2 diabetes, the impact of patent expiration on overall utilization of azithromycin in the U.S., as well as Quantity-based Pricing Mode for Centralized Procurement of Essential Medicines in China. His current research focuses on the impacts of reimbursement for non-face-to-face chronic care management (NFFCCM) services on multiple health outcomes, healthcare utilizations, access to care, and patient's costs among Medicare beneficiaries with diabetes and cardiovascular disease in Louisiana using multiple years’ statewide Medicare claims data.

Research Areas

  • Health Technology Assessment
  • Health Economics
  • Health Policy


Hong, D., Yin, X., & Shi, L. (2021). The COVID Catastrophe: What’s Gone Wrong and How To Stop It Happening Again, 2nd Edition. Emerging Infectious Diseases, 27(11), 2976.

Hong, D., Fort, D., Shi, L., & Price-Haywood, E. G. (2021). Electronic Medical Record Risk Modeling of Cardiovascular Outcomes Among Patients with Type 2 Diabetes. Diabetes Therapy, 1-11.

Monnette, A., Chen, E., Hong, D., Bazzano, A., Dixon, S., Arnold, W. D., & Shi, L. (2021). Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet Journal of Rare Diseases, 16(1), 1-13.

Benton, M., Patel, A. M., Shi, L., Monnette, A., Hong, D., Kruse‐Jarres, R., & Raimundo, K. (2021). Assessing patient and caregiver preferences for treatment of haemophilia A: A discrete choice experiment. Haemophilia, 27(4), e479.

Hong, D., Shen, Y., Monnette, A., Liu, S., Shao, H., Nauman, E., ... & Shi, L. (2020). Does the Encounter Type Matter When Defining Diabetes Complications in Electronic Health Records?. Medical care, 58, S53-S59. 

Hong, D., Si, L., et al. (2019). Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics, 1-42.

Shao, H., Yang, S., Stoecker, C., Fonseca, V., Hong, D., & Shi, L. (2019). Addressing regional differences in diabetes progression: global calibration for diabetes simulation model. Value in Health, 22(12), 1402-1409.

Hong. D. (2017), The Impact of Patent Expiration on Overall Utilization of Azithromycin. Master Thesis. Link: